期刊
VIRUS RESEARCH
卷 228, 期 -, 页码 7-13出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.virusres.2016.11.011
关键词
-
类别
资金
- Council for Chemical Sciences (CW) of the Netherlands Organization for Scientific Research (NWO) through TOP grant [700.57.301]
- Division of Intramural Research (DIR) of the National Institute of Allergy and Infectious Disease (NIAID)
- Novartis (Basel, Switzerland)
Currently, there is no registered treatment for infections with emerging zoonotic coronaviruses like SARS- and MERS-coronavirus. We here report that in cultured cells low-micromolar concentrations of alisporivir, a non-immunosuppressive cyclosporin A-analog, inhibit the replication of four different coronaviruses, including MERS- and SARS-coronavirus. Ribavirin was found to further potentiate the antiviral effect of alisporivir in these cell culture-based infection models, but this combination treatment was unable to improve the outcome of SARS-CoV infection in a mouse model. Nevertheless, our data provide a basis to further explore the potential of Cyp inhibitors as host-directed, broad-spectrum inhibitors of coronavirus replication. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据